2023
Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency
Stecklein S, Barlow W, Pusztai L, Timms K, Kennedy R, Logan G, Seitz R, Badve S, Gökmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi G, Godwin A, Thompson A, Hayes D, Sharma P. Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency. JCO Precision Oncology 2023, 7: e2300197. PMID: 37972336, PMCID: PMC10681491, DOI: 10.1200/po.23.00197.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerHomologous recombination deficiencyBreast cancerAdjuvant anthracycline-based chemotherapyTherapeutic vulnerabilitiesRecombination deficiencyDistinct therapeutic vulnerabilitiesAnthracycline-based chemotherapyImmune response signaturesDNA-damaging therapiesFavorable prognosisIntermediate prognosisWorse prognosisImmunologic microenvironmentImmune responseChemoresistant tumorsPrognostic classificationHeterogeneous diseasePrognosisHeterogeneous groupDistinct subgroupsTumorsCancerResponse signatureSimultaneous assessment
2021
Genomic Determinants of Homologous Recombination Deficiency across Human Cancers
Qing T, Wang X, Jun T, Ding L, Pusztai L, Huang K. Genomic Determinants of Homologous Recombination Deficiency across Human Cancers. Cancers 2021, 13: 4572. PMID: 34572800, PMCID: PMC8472123, DOI: 10.3390/cancers13184572.Peer-Reviewed Original ResearchHRD phenotypeCancer typesPARPi sensitivityPathogenic germline variantsHomologous recombination deficiencyFuture clinical studiesNumber deletionMultiple cancer typesSomatic driver mutationsLung cancerCopy number deletionPolymerase inhibitor treatmentProstate cancerBreast cancerClinical studiesTumor subsetsHRD scoreInhibitor treatmentSomatic genomic dataClinical biomarkersGermline variantsCancerRecombination deficiencyDriver mutationsSynthetic lethality strategy